Gene therapy in prostate cancer: past, present and future

被引：6

作者：

Shirakawa, Toshiro ^{[1
,2
]}

Fujisawa, Masato ^{[2
]}

Gotoh, Akinobu ^{[3
]}

机构：

[1] Kobe Univ, Sch Med, Int Ctr Med Res & Treatment, Div Infect Dis Control,Chuo Ku, Kobe, Hyogo 6500017, Japan

[2] Kobe Univ, Grad Sch Med, Fac Med, Dept Organs Therapeut,Div Urol, Kobe, Hyogo 6500017, Japan

[3] Hyogo Coll Med, Inst Adv Med Sci, Lab Cell & Gene Therapy, Kobe, Hyogo, Japan

来源：

FRONTIERS IN BIOSCIENCE-LANDMARK | 2008年 / 13卷

关键词：

gene; therapy; prostate cancer; clinical trial; review;

D O I：

10.2741/2828

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 [生物化学与分子生物学]; 081704 [应用化学];

摘要：

The absence of effective therapies for hormone refractory prostate cancer establishes the need to develop novel therapeutic modality, such as a gene therapy, that can be applied either separately or in conjunction with current treatment modalities for the treatment of advanced prostate cancer. About 80 protocols for prostate cancer gene therapy have been practiced since 1994. The gene therapy modality is ideal for the treatment of prostate cancer. The disease progress can be precisely monitored by serum-PSA level, the local access is easy by ultra-sound guidance, and prostate as an accessory organ is highly immunogenic. Consequently, the number of prostate cancer gene therapy trials is increasing now. In this paper, we review the previous clinical trials of prostate cancer gene therapy in the chronologic order, and predict the future prospects.

引用

页码：2115 / 2119

页数：5

共 18 条

[1]

Aiuti A, 2002, CURR OPIN MOL THER, V4, P515

[2]

GM-CSF gene-transduced tumor vaccines [J].

Eager, R ;

Nemunaitis, J .

MOLECULAR THERAPY, 2005, 12 (01) :18-27

[3]

Freytag SO, 2003, CANCER RES, V63, P7497

[4]

In situ gene therapy for adenocarcinoma of the prostate:: A phase I clinical trial [J].

Herman, JR ;

Adler, HL ;

Aguilar-Cordova, E ;

Rojas-Martinez, A ;

Woo, S ;

Timme, TL ;

Wheeler, TM ;

Thompson, TC ;

Scardino, PT .

HUMAN GENE THERAPY, 1999, 10 (07) :1239-1249

[5]

Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University [J].

Hinata, Nobuyuki ;

Shirakawa, Toshiro ;

Terao, Shuji ;

Goda, Kazumasa ;

Tanaka, Kazushi ;

Yamada, Yuji ;

Hara, Isao ;

Kamidono, Sadao ;

Fujisawa, Masato ;

Gotoh, Akinobu .

INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (06) :834-837

[6]

Cancer statistics, 2003 [J].

Jemal, A ;

Murray, T ;

Samuels, A ;

Ghafoor, A ;

Ward, E ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :5-26

[7]

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer [J].

Kubo, H ;

Gardner, TA ;

Wada, Y ;

Koeneman, KS ;

Gotoh, A ;

Yang, L ;

Kao, CH ;

Lim, SD ;

Amin, MB ;

Yang, H ;

Black, ME ;

Matsubara, S ;

Nakagawa, M ;

Gillenwater, JY ;

Zhau, HYE ;

Chung, LWK .

HUMAN GENE THERAPY, 2003, 14 (03) :227-241

[8]

Clinical trials of immunotherapy for advanced prostate cancer [J].

Kuratsukuri, K ;

Nishisaka, N ;

Jones, RF ;

Wang, CY ;

Haas, GP .

UROLOGIC ONCOLOGY, 2000, 5 (06) :265-273

[9]

Oncolytic adenoviruses - selective retargeting to tumor cells [J].

Mathis, JM ;

Stoff-Khalili, MA ;

Curiel, DT .

ONCOGENE, 2005, 24 (52) :7775-7791

[10]

Clinical evaluation of adenoviral-mediated p53 gene transfer: Review of INGN 201 studies [J].

Merritt, JA ;

Roth, JA ;

Logothetis, CJ .

SEMINARS IN ONCOLOGY, 2001, 28 (05) :105-114

← 1 2 →